Ladenburg Thalmann analyst Ahu Demir downgrades Ayala Pharmaceuticals (OTC:ADXS) from Buy to Neutral.
Save time and jump to the most important pieces.
Ladenburg Thalmann analyst Ahu Demir downgrades Ayala Pharmaceuticals (OTC:ADXS) from Buy to Neutral.
Upgrades Alliance Global Partners upgraded the previous rating for KNOT Offshore Partners LP (NYSE:KNOP) from Neutral to Buy. KNOT Offshore Partners earned $0.04 in the first quarter, compared to $0.79 in the year-ago quarter. The stock has a 52-week-high of $18.67 and a 52-week-low of $4.28. At the end of the last trading period, KNOT Offshore Partners closed at $4.80. Ladenburg Thalmann upgraded the previous rating for Advaxis Inc (OTC:ADXS) from Neutral to Buy. The stock has a 52-week-high of $7.20 and a 52-week-low of $0.65. At the end of the last trading period, Advaxis closed at $0.85. For ChargePoint Holdings Inc (NYSE:CHPT), B of A Securities upgraded the previous rating of Neu
Ladenburg Thalmann analyst Ahu Demir upgrades Advaxis (OTC:ADXS) from Neutral to Buy and announces $4 price target.
SUZHOU, China and ROCKVILLE, Md., April 2, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced its appointment of Dr. David Sidransky, MD., a renowned oncologist, to the company's Board of Directors as an independent non-executive director, effective on March 31, 2021. Known for in research in biomarkers for early detection and therapy and profiled by TIME magazine in 2001 as one of America's best in science and medicine, Dr. Sidransky is a leading expert in oncology and precision medicine widely respected in the biophar
15-12G - Ayala Pharmaceuticals, Inc. (0001100397) (Filer)
10-K/A - Ayala Pharmaceuticals, Inc. (0001100397) (Filer)
8-K/A - Ayala Pharmaceuticals, Inc. (0001100397) (Filer)
MONMOUTH JUNCTION, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX:ADXS), a clinical-stage oncology company, today announced that it filed a Form 15 with the Securities and Exchange Commission (the "SEC") to deregister its common stock under Section 12(g) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and to suspend its reporting obligations under Section 15(d) of the Exchange Act. The Company's obligation to file periodic reports with the SEC, including reports on Forms 10-K, 10-Q and 8-K, will be suspended immediately upon filing of the Form 15. Once the Form 15 is effective, which is expected to occur within 90 days of filing, the Comp
MONMOUTH JUNCTION, N.J., March 26, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX:ADXS), a clinical-stage oncology company, today announced the completion of the previously announced sale of AL102, and related drug candidate AL101, to Immunome, Inc. (NASDAQ:IMNM). As per the terms of the sale, Ayala received from Immunome $20 million in cash and 2,175,489 shares of Immunome common stock, and Immunome assumed specified liabilities related to AL102. Ayala may also receive up to an additional $37.5 million in development and commercial milestone payments. "We are pleased that AL102 will now be advanced by the highly experienced team at Immunome," said Ken Berlin, President and
– Immunome entered into a definitive asset purchase agreement with Ayala to acquire AL102 earlier this month – Immunome, Inc. (NASDAQ:IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today recognized the announcement by Ayala Pharmaceuticals, Inc. (OTCQX:ADXS), a clinical-stage oncology company, that patient enrollment has been completed in the Phase 3 RINGSIDE study evaluating AL102 in desmoid tumors. Earlier this month, Immunome announced that it entered into a definitive asset purchase agreement with Ayala to acquire AL102 and related drug candidate AL101. Completion of the transaction remains subject to customary clos
Data show enhanced anti-tumor activity of AL102 over time Registration-enabling Phase 3 segment of RINGSIDE is enrolling patients globally Company to host conference call and webcast to discuss updated Phase 2 results on Wednesday, June 7 REHOVOT, Israel and MONMOUTH JUNCTION, N.J., June 05, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX:ADXS), a clinical-stage oncology company, today announced further results from the Phase 2 (Part A) segment of the RINGSIDE study evaluating AL102 in desmoid tumors. The results were presented in a Poster Discussion Session at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting on Saturday, June 3. AL102 is a once-daily, po
REHOVOT, Israel and MONMOUTH JUNCTION, N.J., Feb. 10, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (f/k/a Advaxis Inc.) (the "Company," "New Ayala," "we," "us" or "our") (OTCQX:ADXS), a clinical-stage oncology company, today announces financial results for the fiscal year ended October 31, 2022. Management Commentary "We were pleased to close our previously announced merger in January 2023," said Kenneth A. Berlin, President and Chief Executive Officer of the Company. "Our immediate priorities include executing on Part B of the ongoing registration-enabling RINGSIDE study evaluating AL102 in desmoid tumors. We believe that AL102 has best in class potential and, if approved, m
Merger brings U.S. management and presence, cash to develop compelling late-stage asset Lead candidate AL102 being evaluated in ongoing Phase 2/3 RINGSIDE study, a potential registration trial in desmoid tumors Ayala and Advaxis stockholders will respectively own approximately 62.5% and 37.5% Combined Company to Seek Uplisting to Nasdaq Conference Call and Webcast today at 8:00am ET REHOVOT, Israel and WILMINGTON, Del. and MONMOUTH JUNCTION, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA) (Ayala), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressi
4 - Ayala Pharmaceuticals, Inc. (0001100397) (Issuer)
SC 13G/A - Ayala Pharmaceuticals, Inc. (0001100397) (Subject)
SC 13D/A - Ayala Pharmaceuticals, Inc. (0001100397) (Subject)
SC 13G/A - Ayala Pharmaceuticals, Inc. (0001100397) (Subject)
4 - Ayala Pharmaceuticals, Inc. (0001100397) (Issuer)
4 - Ayala Pharmaceuticals, Inc. (0001100397) (Issuer)
4 - Ayala Pharmaceuticals, Inc. (0001100397) (Issuer)